Scleroderma (Systemic Sclerosis)

• Initial endothelial injury and vasculopathy: Endothelial cell injury—triggered by oxidative stress, circulating autoantibodies (particularly anti-VEGF antibodies and anti-endothelial cell antibodies), and complement deposition—leads to increased endothelial permeability and dysfunction. This causes recurrent microvascular injury, abnormal vasoreactivity (manifesting as Raynaud phenomenon), and a pro-thrombotic state. Loss of nitric oxide (NO) production and increased endothelin-1 (ET-1) expression perpetuate vasoconstriction and ischemic injury to tissues. The resulting hypoxia triggers both innate and adaptive immune responses while simultaneously activating resident fibroblasts through TGF-β signaling and hypoxia-inducible factor (HIF-1α) pathways.

• Immune activation and autoantibody production: A dysregulated adaptive immune response generates pathognomonic autoantibodies—anti-centromere (ACA), anti-topoisomerase-I (anti-Scl-70), and anti-RNA polymerase III (RNAP III) antibodies—via B cell hyperactivation and impaired T regulatory cell (Treg) function. Th17 cell differentiation is enhanced, promoting IL-17 and IL-6 production, which recruit immune cells to affected tissues. Innate immune activation occurs through pattern-recognition receptors recognizing danger-associated molecular patterns (DAMPs), leading to inflammasome activation and IL-1β production. Circulating immune complexes deposit in small vessels, triggering complement-mediated inflammation. Fibroblast-derived danger signals (including heat shock proteins) perpetuate this inflammatory milieu.

• Fibroblast activation and excessive collagen deposition: The convergence of TGF-β signaling (both canonical Smad2/3-dependent and non-canonical pathways), platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF), ET-1, and cytokines (IL-6, IL-13) activates quiescent fibroblasts to a myofibroblast phenotype. Myofibroblasts are characterized by α-smooth muscle actin (α-SMA) expression and enhanced production of extracellular matrix proteins (types I and III collagen, fibronectin). Enhanced TIMPs (tissue inhibitors of metalloproteinases) relative to MMPs (matrix metalloproteinases) shift the balance toward matrix accumulation. Epithelial-mesenchymal transition (EMT) of alveolar epithelial cells, dermal fibroblasts, and even endothelial cells (endothelial-mesenchymal transition, EndoMT) expand the pool of matrix-producing cells. Abnormal mechanotransduction via integrin signaling and altered mechanobiology create positive feedback loops where tissue stiffness further perpetuates fibroblast activation.

• Vasculature remodeling and microvascular rarefaction: Progressive loss of capillaries—evident in nailfold capillary microscopy—combined with proliferation of surviving vessels creates characteristic abnormal patterns. Angiogenic defects result from circulating endothelial progenitor cell dysfunction, reduced VEGF signaling (despite elevated VEGF levels, suggesting receptor dysfunction), and loss of the angiopoietin-Tie2 axis. This microvascular rarefaction underpins both ischemic manifestations (digital ulcers, pulmonary hypertension) and progressive organ fibrosis through chronic hypoxia and impaired perfusion.

• Genetics and epigenetics: While SSc lacks a single Mendelian inheritance pattern, genome-wide association studies (GWAS) have identified susceptibility loci in HLA genes (particularly HLA-DRB1 and HLA-DQA1), as well as non-HLA loci affecting T cell signaling (STAT4, IRF5, FAM167A-BLK), B cell activation (PRD1-BF1), and immune tolerance pathways (TNIP1, TNFAIP3). Epigenetic changes—including altered DNA methylation of immune-related genes, reduced histone deacetylase activity in fibroblasts, and microRNA dysregulation (particularly miR-29, which regulates collagen synthesis)—amplify the disease phenotype. These genetic predispositions likely require environmental triggers for disease manifestation.

• Female sex: The 3–4:1 female-to-male predominance suggests both hormonal factors (estrogen as a potential B cell and fibroblast activator) and X-linked genetic effects as primary risk factors. Women of reproductive age are disproportionately affected, though SSc can occur at any age.

• Environmental and occupational exposures: Chronic exposure to silica dust (miners, stonemasons, sandblasters, farmers) carries a well-established increased risk, with a 3–5 fold elevation in SSc incidence. The silica-exposed population often manifests aggressive dcSSc with early pulmonary fibrosis. Organic solvents (trichloroethylene, toluene, benzene) have been implicated in several cohort and case-control studies. Raynaud phenomenon and scleroderma-like lesions have been reported in workers with prolonged vinyl chloride exposure (leading to Raynaud phenomenon, skin sclerosis, and osteolysis). Other proposed triggers include epoxy resins, pesticides, and graft-versus-host disease (GVHD) in bone marrow transplant recipients.

• Genetic susceptibility: Familial clustering is rare but documented; first-degree relatives of SSc patients have approximately 1–2% risk, compared to 0.01–0.1% population prevalence. HLA alleles (HLA-DRB1*1104, DRB1*1301) show strong associations with anti-Scl-70 seropositivity and dcSSc, while HLA-DQA1*0501 associates with ACA and lcSSc. Non-HLA genes (STAT4, IRF5, BLK, TNIP1, TNFAIP3) contribute modest genetic risk.

• Estrogen and hormonal factors: The female predominance persists across reproductive and post-menopausal ages, suggesting complex hormonal interactions beyond simple estrogen excess. Estrogen receptor signaling may enhance B cell activation and reduce Treg differentiation. Pregnancy can precede or exacerbate SSc in some women, though causality remains unclear.

• Prior chemotherapy and radiation: Patients receiving chemotherapy agents (particularly taxanes and gemcitabine) or mantle field radiation for lymphoma or breast cancer develop chemotherapy-associated or radiation-associated scleroderma, typically within 5–10 years of exposure.

• Drug-associated scleroderma: L-tryptophan contamination caused an epidemic of eosinophilia-myalgia syndrome (EMS) in 1989, which presented with scleroderma-like features. More recently, appetite suppressants, docetaxel, and some immunotherapy agents have been implicated in rare scleroderma cases, though the pathophysiology differs from idiopathic SSc.

• Raynaud phenomenon: The most frequent initial manifestation, occurring in >90% of SSc patients. Episodes involve triphasic color changes—white (vasospasm and ischemia), blue (desaturation and static blood), then red (reactive hyperemia)—typically triggered by cold exposure or emotional stress and lasting minutes to hours. In SSc, Raynaud is often severe, asymmetric, prolonged, and associated with digital ulcers or tissue necrosis (secondary Raynaud), distinguishing it from primary Raynaud in the general population. The pathophysiology involves excessive α-adrenergic responsiveness, reduced endothelial nitric oxide, increased endothelin-1, and structural vessel wall abnormalities.

• Skin sclerosis and fibrosis: The hallmark cutaneous feature involves symmetric, induration of the skin with loss of normal elasticity and texture. The distribution defines disease subtype: limited cutaneous SSc (lcSSc) features fibrosis limited to the face, neck, upper chest, and areas distal to the elbows and knees (sparing proximal limbs, trunk); diffuse cutaneous SSc (dcSSc) involves extensive fibrosis of the proximal limbs, trunk, and sometimes the abdomen and genitalia. Early disease presents with edematous, puffy fingers (pre-fibrotic phase); progression leads to shiny, taut, waxy skin with effacement of skin folds and loss of hair. Hyperpigmentation interspersed with hypopigmentation ("salt-and-pepper" appearance) may occur, particularly over fibrotic areas. In dcSSc, rapid progression within the first 3–5 years portends worse prognosis.

• Facial changes: Characteristic facial involvement includes microstomia (restricted mouth opening from perioral fibrosis, limiting dental hygiene and food intake), tightening of facial skin creating a "mask-like" facies, and prominent perioral radial fissuring. In lcSSc, facial involvement is often spared or mild (CREST syndrome, a lcSSc variant, presents with Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, and Telangiectasia without extensive facial fibrosis).

• Esophageal dysmotility and GI involvement: Present in 75–90% of SSc, ranging from asymptomatic motility abnormalities to severe symptoms. Dysphagia (difficulty swallowing solids more than liquids) and GERD (gastroesophageal reflux disease) result from aperistalsis in the lower two-thirds of the esophagus and incompetence of the lower esophageal sphincter (LES). The fibrotic, atonic esophagus is prone to retained food and bacterial overgrowth. Severe reflux increases risk of Barrett esophagus and esophageal adenocarcinoma. Gastric dysmotility presents as postprandial fullness, early satiety, and bloating. Small bowel involvement causes malabsorption, bacterial overgrowth, and pseudo-obstruction. Colonic fibrosis leads to constipation and fecal impaction; in dcSSc, large-mouth diverticula (analogous to colonic "blowouts") can perforate.

• Digital ulcers and gangrenous lesions: Occur in approximately 50% of SSc patients, particularly in dcSSc. Ulcers typically develop over pressure points (fingertips, knuckle prominences) and result from progressive microvascular rarefaction and tissue ischemia. Painful and slow-healing, these lesions significantly impair function and predispose to secondary infection. Severe digital ischemia may progress to autoinfarction and gangrene, necessitating amputation.

• Joint involvement: Non-erosive polyarthritis, particularly affecting the hands (PIP, MCP joints), wrists, and knees, occurs in 30–50% of SSc patients. Symptoms include morning stiffness, swelling, and pain, typically mild and non-deforming. Sclerodactyly (skin fibrosis of fingers with loss of normal contours) contributes to progressive hand contractures and functional loss. Rarely, erosive arthropathy and joint destruction occur, especially with anti-RNAP III antibodies. Carpal tunnel syndrome is frequent due to perivascular fibrosis.

• Pulmonary manifestations:
• Pulmonary arterial hypertension (PAH) develops in 10–15% of SSc, more commonly in lcSSc, and represents a leading cause of SSc-related mortality. PAH results from endothelial dysfunction, microvascular rarefaction, and abnormal smooth muscle proliferation. Presenting symptoms include dyspnea on exertion, syncope, and chest discomfort; physical findings include right ventricular heave, loud P2, and peripheral edema.
• Interstitial lung disease (ILD) and pulmonary fibrosis occur in 40–75% of SSc, more frequently in dcSSc, particularly with anti-Scl-70 antibodies. Subpleural and basilar predominance is typical. Insidious dyspnea, nonproductive cough, and reduced exercise capacity develop over years. Progressive ILD is a major cause of SSc mortality.
• Aspiration risk from esophageal dysmotility increases pneumonia risk, particularly in severe cases.

• Renal crisis (scleroderma renal crisis, SRC): A medical emergency occurring in 5–10% of SSc, predominantly in dcSSc with anti-RNAP III antibodies and within the first 4 years of skin disease onset. Presents with acute-onset hypertension (often >180/120 mmHg), acute kidney injury (AKI), thrombotic microangiopathy (TMA), and microangiopathic hemolytic anemia (MAHA). Pathophysiology involves endothelial injury, renin-angiotensin system activation, and intimal proliferation in renal arterioles, leading to a thrombotic microangiopathy ("onion-skinning"). Patients often report no preceding symptoms; SRC may present insidiously with rising creatinine or dramatically with hypertensive encephalopathy, pulmonary edema, or seizures. Without treatment, rapid progression to end-stage renal disease (ESRD) occurs within weeks.

• Cardiac involvement: While overt cardiac disease is less common than in other connective tissue diseases, SSc can cause myocardial fibrosis (resulting in conduction abnormalities, arrhythmias, and diastolic dysfunction), pericarditis, pericardial effusion, and myocarditis. Sudden cardiac death from arrhythmias may occur. Coronary vasospasm (driven by endothelin-1 excess and abnormal sympathetic tone) can precipitate anginal symptoms.

• Renal glomerulonephritis: Distinct from SRC, SSc-associated glomerulonephritis (particularly membranoproliferative or proliferative forms) occurs in a minority of patients and may present with proteinuria, hematuria, and progressive renal dysfunction without hypertensive urgency.

• Thyroid disease: Hypothyroidism (often primary autoimmune thyroiditis) develops in 10–20% of SSc, especially in anti-Scl-70+ patients. Hyperthyroidism and Graves disease are rarer.

• Musculoskeletal symptoms: Myalgia and myositis (elevation of creatine kinase, inflammatory infiltrates on biopsy) occur in a minority but may cause significant disability. Muscle fibrosis leads to progressive weakness.

• Classification criteria: The 2013 ACR/EULAR classification criteria (revised in the absence of specific diagnostic criteria) identify SSc with high sensitivity and specificity. Criteria include: (1) skin thickening of fingers extending proximal to the metacarpophalangeal joints (sufficient for classification) OR (2) a weighted combination of skin features (puffy hands, sclerodactyly, fingertip ulcers/pitted scars) plus vascular features (nailfold capillary abnormalities, abnormal nailfold capillaroscopy, Raynaud phenomenon) plus organ involvement (pulmonary artery systolic pressure >40 mmHg on echocardiography, ILD on high-resolution CT [HRCT], SSc-specific autoantibody positivity). The 2013 criteria improve early disease recognition

Emergency — scleroderma renal crisis

• ACE inhibitor (captopril): start immediately and titrate upward every few hours; the short half-life makes captopril the agent of choice for rapid titration. Continue even as creatinine rises or dialysis is started — renal recovery may occur months later. ACE inhibitors are absolutely contraindicated in pregnancy; they are also not recommended prophylactically, as pre-treatment may worsen outcomes.
• Avoid glucocorticoids ≥15 mg prednisone equivalent daily: steroid exposure is the best-established precipitant of renal crisis and is discouraged in diffuse disease.

Vasculopathy (Raynaud, digital ulcers)

• Dihydropyridine calcium channel blockers (nifedipine, extended-release): first-line vasodilator; add cold avoidance, smoking cessation, and withdrawal of nonselective beta blockers, triptans, and sympathomimetics.
• PDE5 inhibitors (sildenafil) and topical nitrates: second-line or add-on for refractory attacks and ulcer healing; do not combine PDE5 inhibitors with nitrates.
• IV prostacyclin analogues (epoprostenol/iloprost): for critical digital ischemia or non-healing ulcers.
• Endothelin receptor antagonists (bosentan): reduce new digital ulcers in recurrent-ulcer patients; hepatotoxic and teratogenic.

Fibrotic and inflammatory disease

• Mycophenolate mofetil: preferred first-line immunosuppressant for SSc-ILD and progressive skin thickening (Scleroderma Lung Study II showed comparable efficacy to cyclophosphamide with better tolerability).
• Cyclophosphamide or tocilizumab (anti–IL-6 receptor) and rituximab: escalation options; nintedanib (antifibrotic tyrosine kinase inhibitor) slows FVC decline in SSc-ILD.
• Methotrexate: option for early diffuse skin disease without significant organ involvement.
• Autologous hematopoietic stem cell transplantation: definitive disease-modifying option in rapidly progressive early dcSSc with organ involvement, at experienced centers, weighed against treatment-related mortality.

Pulmonary arterial hypertension and GI disease

• PAH: confirm by right heart catheterization, then treat per ESC/ERS pulmonary hypertension guidance with upfront combination ERA plus PDE5 inhibitor, escalating to prostacyclin pathway agents; calcium channel blocker monotherapy is inappropriate in SSc-PAH.
• GI: proton pump inhibitors for reflux, prokinetics for dysmotility, and rotating antibiotics (rifaximin) for bacterial overgrowth.

Emergencies

• Scleroderma renal crisis: renin-driven malignant hypertension with thrombotic microangiopathy; signaled by abrupt severe hypertension, rising creatinine, schistocytes with thrombocytopenia, headache, seizure, or flash pulmonary edema. A normotensive variant occurs in steroid-exposed patients — a rising creatinine with hemolysis is the clue.
• Critical digital ischemia/gangrene: microvascular rarefaction plus vasospasm produces a cold, dusky, exquisitely painful digit with demarcation; requires urgent vasodilator therapy and prostanoid infusion before autoamputation.
• Right heart failure from PAH: rising pulmonary vascular resistance decompensates the thin-walled RV; syncope, ascites, elevated JVP, and a loud P2 signal advanced disease. An isolated fall in DLCO out of proportion to FVC is the earliest screening clue.
• GI perforation from pseudo-obstruction or large-mouthed diverticula: distension with peritonitis and free air.

Chronic disease complications

• Progressive ILD: myofibroblast-driven basilar fibrosis; declining FVC/DLCO with Velcro crackles and reticulation on HRCT.
• Gastric antral vascular ectasia (GAVE): watermelon stomach on endoscopy causing iron-deficiency anemia and occult bleeding; treated endoscopically with argon plasma coagulation.
• Barrett esophagus and adenocarcinoma: consequence of aperistalsis plus an incompetent LES.
• Malabsorption from small intestinal bacterial overgrowth: weight loss, steatorrhea, fat-soluble vitamin deficiency.
• Myocardial fibrosis: patchy contraction-band and replacement fibrosis producing conduction block, ventricular arrhythmia, and diastolic failure — a cause of sudden death.
• Malignancy: anti-RNA polymerase III positivity clusters with cancer diagnosed close to SSc onset, prompting age-appropriate screening.

Treatment-related complications

• Glucocorticoids: precipitate renal crisis — the single most important iatrogenic hazard.
• Cyclophosphamide: hemorrhagic cystitis and bladder cancer (acrolein metabolite), gonadal failure, myelosuppression.
• Mycophenolate: teratogenicity, cytopenias, opportunistic infection.
• Tocilizumab/rituximab: infection, bowel perforation, hepatitis B reactivation.
• Bosentan: hepatotoxicity and teratogenicity; nintedanib: diarrhea and transaminitis; PDE5 inhibitor with nitrate: profound hypotension.

• Antibody–phenotype pairing is the most tested association: anti-centromere → limited cutaneous SSc/*CREST*, higher risk of isolated PAH; anti-topoisomerase I (Scl-70) → diffuse disease with ILD; anti-RNA polymerase III → rapidly progressive skin thickening, renal crisis, and coincident malignancy. ANA is positive in nearly all patients but is not subtype-specific.
• Best next step in renal crisis is an ACE inhibitor, not dialysis or steroids: a dcSSc patient within a few years of onset with blood pressure >180/120, acute kidney injury, schistocytes, and low platelets needs captopril titrated aggressively. Its short half-life allows rapid uptitration — but remember all ACE inhibitors are contraindicated in pregnancy.
• The classic distractor is TTP: MAHA plus thrombocytopenia plus AKI looks identical, but SSc history, severe hypertension, and normal ADAMTS13 activity point to renal crisis. Plasma exchange is the wrong answer.
• Steroids are the trap: reaching for high-dose prednisone for "tight skin" or arthritis can precipitate renal crisis, including a normotensive variant.
• Nailfold capillaroscopy separates primary from secondary Raynaud: dilated, dropped-out capillaries with hemorrhages mean an underlying connective tissue disease; a normal pattern with normal ANA favors benign primary Raynaud.
• Esophageal manometry shows absent distal peristalsis with a hypotensive LES — the mirror image of achalasia, where the LES fails to relax.
• Isolated low DLCO with preserved FVC suggests PAH; low DLCO plus low FVC suggests ILD — annual echocardiography and PFTs are the standard screening pair.
• Mimic to rule out: eosinophilic fasciitis gives peau d'orange skin with a groove sign, peripheral eosinophilia, no Raynaud, and characteristically spares the fingers; morphea is localized skin disease without systemic involvement; anti-U1 RNP with overlapping myositis and puffy hands suggests mixed connective tissue disease.